The Role of Bioenergetics in Neurodegeneration

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 26

PMID 36012480

Authors

Taylor A Strope

Cole J Birky

Heather M Wilkins

Affiliations

Soon will be listed here.

Abstract

Bioenergetic and mitochondrial dysfunction are common hallmarks of neurodegenerative diseases. Decades of research describe how genetic and environmental factors initiate changes in mitochondria and bioenergetics across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Mitochondria control many cellular processes, including proteostasis, inflammation, and cell survival/death. These cellular processes and pathologies are common across neurodegenerative diseases. Evidence suggests that mitochondria and bioenergetic disruption may drive pathological changes, placing mitochondria as an upstream causative factor in neurodegenerative disease onset and progression. Here, we discuss evidence of mitochondrial and bioenergetic dysfunction in neurodegenerative diseases and address how mitochondria can drive common pathological features of these diseases.

Citing Articles

Mitochondrial Dysfunction as a Potential Mechanism Mediating Cardiac Comorbidities in Parkinson's Disease.

Salis Torres A, Lee J, Caporali A, Semple R, Horrocks M, Macrae V Int J Mol Sci. 2024; 25(20).

PMID: 39456761 PMC: 11507255. DOI: 10.3390/ijms252010973.

Recent advances in mitochondria-targeting theranostic agents.

Qian K, Gao S, Jiang Z, Ding Q, Cheng Z Exploration (Beijing). 2024; 4(4):20230063.

PMID: 39175881 PMC: 11335472. DOI: 10.1002/EXP.20230063.

Brain development and bioenergetic changes.

Rajan A, Fame R Neurobiol Dis. 2024; 199:106550.

PMID: 38849103 PMC: 11495523. DOI: 10.1016/j.nbd.2024.106550.

Nucleocytoplasmic transport rates are regulated by cellular processes that modulate GTP availability.

Scott K, Halfmann C, Hoefakker A, Purkayastha P, Wang T, Lele T J Cell Biol. 2024; 223(7).

PMID: 38683248 PMC: 11059771. DOI: 10.1083/jcb.202308152.

The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson's Disease.

Neha , Mazahir I, Khan S, Kaushik P, Parvez S Mol Neurobiol. 2024; 61(10):8086-8103.

PMID: 38468113 DOI: 10.1007/s12035-024-04078-8.

References

Tohgi H, Yonezawa H, Takahashi S, Sato N, Kato E, Kudo M . Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology. 1998; 40(3):131-7. DOI: 10.1007/s002340050553. View

Wong P, Pardo C, Borchelt D, Lee M, Copeland N, Jenkins N . An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14(6):1105-16. DOI: 10.1016/0896-6273(95)90259-7. View

Weidling I, Wilkins H, Koppel S, Hutfles L, Wang X, Kalani A . Mitochondrial DNA Manipulations Affect Tau Oligomerization. J Alzheimers Dis. 2020; 77(1):149-163. PMC: 7962146. DOI: 10.3233/JAD-200286. View

Mecocci P, MacGarvey U, Beal M . Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994; 36(5):747-51. DOI: 10.1002/ana.410360510. View

Bellenguez C, Kucukali F, Jansen I, Kleineidam L, Moreno-Grau S, Amin N . New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022; 54(4):412-436. PMC: 9005347. DOI: 10.1038/s41588-022-01024-z. View

Higgins C, Jung C, Xu Z . ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 2003; 4:16. PMC: 169170. DOI: 10.1186/1471-2202-4-16. View

Venereau E, Ceriotti C, Bianchi M . DAMPs from Cell Death to New Life. Front Immunol. 2015; 6:422. PMC: 4539554. DOI: 10.3389/fimmu.2015.00422. View

Pasinelli P, Belford M, Lennon N, Bacskai B, Hyman B, Trotti D . Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004; 43(1):19-30. DOI: 10.1016/j.neuron.2004.06.021. View

Feng D, Liu L, Zhu Y, Chen Q . Molecular signaling toward mitophagy and its physiological significance. Exp Cell Res. 2013; 319(12):1697-1705. DOI: 10.1016/j.yexcr.2013.03.034. View

10.

Silva D, Selfridge J, Lu J, E L, Roy N, Hutfles L . Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet. 2013; 22(19):3931-46. PMC: 3888119. DOI: 10.1093/hmg/ddt247. View

11.

Cutler N . Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1986; 10(3-5):309-21. DOI: 10.1016/0278-5846(86)90010-2. View

12.

Yamada E, Respondek G, Mussner S, de Andrade A, Hollerhage M, Depienne C . Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice. Exp Neurol. 2014; 253:113-25. DOI: 10.1016/j.expneurol.2013.12.017. View

13.

Heikkila R, Cohen G . Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine. Science. 1971; 172(3989):1257-8. DOI: 10.1126/science.172.3989.1257. View

14.

Onyango I, Bennett J, Stokin G . Regulation of neuronal bioenergetics as a therapeutic strategy in neurodegenerative diseases. Neural Regen Res. 2021; 16(8):1467-1482. PMC: 8323696. DOI: 10.4103/1673-5374.303007. View

15.

Tsai Y, Coady T, Lu L, Zheng D, Alland I, Tian B . ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 2020; 34(11-12):785-805. PMC: 7263147. DOI: 10.1101/gad.335836.119. View

16.

Sasaki S, Warita H, Murakami T, Abe K, Iwata M . Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. 2004; 107(5):461-74. DOI: 10.1007/s00401-004-0837-z. View

17.

Singh T, Jiao Y, Ferrando L, Yablonska S, Li F, Horoszko E . Neuronal mitochondrial dysfunction in sporadic amyotrophic lateral sclerosis is developmentally regulated. Sci Rep. 2021; 11(1):18916. PMC: 8460779. DOI: 10.1038/s41598-021-97928-7. View

18.

Hoglinger G, Carrard G, Michel P, Medja F, Lombes A, Ruberg M . Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem. 2003; 86(5):1297-307. DOI: 10.1046/j.1471-4159.2003.01952.x. View

19.

Pellegrino M, Nargund A, Haynes C . Signaling the mitochondrial unfolded protein response. Biochim Biophys Acta. 2012; 1833(2):410-6. PMC: 3393825. DOI: 10.1016/j.bbamcr.2012.02.019. View

20.

Fukui H, Diaz F, Garcia S, Moraes C . Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2007; 104(35):14163-8. PMC: 1955773. DOI: 10.1073/pnas.0705738104. View